Evimed Information

Evimed is a specialist consultancy supporting pharmaceutical and biotech companies through the evidence and market access challenges that determine whether a medicine reaches patients — and at what price. We work with global and affiliate teams on the technical work behind HTA submissions and pricing decisions: evidence synthesis, health economic modelling, statistical analysis, and the localisation of global deliverables for individual markets. Our clients come to us for analytical work that is technically rigorous and decision-ready — models and analyses that hold up under HTA scrutiny. Our team brings combined experience across 100+ HTA submissions and 300+ localisations in 20+ countries, with particular depth in immunology, oncology, specialty care, and neuroscience. What we do: Evidence synthesis — systematic, targeted, and rapid literature reviews; indirect treatment comparisons, network meta-analysis, MAIC, and ML-NMR Health economic modelling — cost-effectiveness, budget impact, and bespoke models, plus independent QC and validation Statistical analysis — survival analysis, treatment switching, utility/QoL analyses, healthcare resource use, and post-hoc trial analyses HTA and reimbursement strategy — submission strategy, outcome and risk assessment, competitive positioning, and pipeline/BD asset evaluation Localisation — adapting global SLR, NMA, and HE deliverables for local markets, including the UK, France, Canada, the Nordics, and Portugal Discussing an upcoming submission or pipeline decision? Get in touch — or follow the page for our latest HEOR and HTA work.